Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1838]

Healthcare delivery for non-communicable diseases among breast cancer survivors...

Dr Sanjeeva Gunasekera - National Cancer Institute, Maharagama, Sri Lanka

Healthcare delivery for non-communicable diseases among breast cancer survivors in Sri Lanka: Is there a missed opportunity? ( Dr Sanjeeva Gunasekera - National Cancer Institute, Maharagama, Sri Lanka )

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+...

Dr Javier Cortés - Hospital Universitario Ramón y Cajal, Madrid, Spain

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer ( Dr Javier Cortés - Hospital Universitario Ramón y Cajal, Madrid, Spain )

ESMO 2021: Breast cancer roundup

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ESMO 2021: Breast cancer roundup ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally...

Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )

Assessment of guideline adherence in breast cancer management among oncologists...

Dr Bolanle Adegboyega - Lagos University Teaching Hospital, Lagos, Nigeria

Assessment of guideline adherence in breast cancer management among oncologists in Nigeria ( Dr Bolanle Adegboyega - Lagos University Teaching Hospital, Lagos, Nigeria )

ESMO 2021 Roundup

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

OncoAlert and ecancer - ESMO 2021 Day 5

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post...

Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer ( Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

OncoAlert and ecancer - ESMO 2021 Day 4

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 4 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

OncoAlert and ecancer - ESMO 2021 Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer

Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center...

First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer ( Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Houston, Texas )

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple...

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

More from ecancer